Kenneth Murray, MD
Neurology · Cullman, ALNPI 1265594733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $961, 2.6 times the $366 reported in 2019. That places this record below the midpoint for neurology clinicians in AL, where the typical reported total is $2,219.
Across 127 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$318
- Axsome Therapeutics, Inc.$290
- Eisai Inc.$248
- Lilly USA, LLC$220
- Neurocrine Biosciences, Inc.$154
- AbbVie$146
- plus $1K from 27 others
Across 2 payments — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$2K
What the payments were for
- Speaking & faculty fees$241%
- Food & beverage$2,48299%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 17 | $318 |
| Axsome Therapeutics, Inc. | 14 | $290 |
| Eisai Inc. | 11 | $248 |
| Lilly USA, LLC | 12 | $220 |
| Neurocrine Biosciences, Inc. | 5 | $154 |
| AbbVie | 6 | $146 |
| Harmony Biosciences LLC | 3 | $121 |
| GE HealthCare | 13 | $105 |
| Livanova USA, Inc. | 6 | $94 |
| Neurelis, Inc. | 5 | $86 |
| Acadia Pharmaceuticals Inc | 3 | $78 |
| Baxter Healthcare | 3 | $73 |
| Biogen | 3 | $61 |
| Philips North America LLC | 3 | $55 |
| UCB, Inc. | 2 | $38 |
| Grifols USA, LLC | 2 | $35 |
| Sanofi | 1 | $32 |
| Pfizer | 2 | $32 |
| AstraZeneca | 2 | $32 |
| Mylan Specialty L.p. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| CSL Behring | 1 | $28 |
| Amgen | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Ceribell, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,519 in reported general payments places this provider in the 50th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $147,893 |
| NuplazidPimavanserin Tartrate | 12 | $60,778 |
| BriviactBrivaracetam | 25 | $36,366 |
| UbrelvyUbrogepant | 24 | $27,975 |
| NourianzIstradefylline | 13 | $24,987 |
| Nurtec OdtRimegepant Sulfate | 22 | $23,554 |
| LamictalLamotrigine | 13 | $21,284 |
| NeuproRotigotine | 14 | $16,033 |
| QuliptaAtogepant | 13 | $15,883 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $14,461 |
| XcopriCenobamate | 12 | $14,240 |
| Rivastigmine | 53 | $10,010 |
| Lacosamide | 37 | $6,927 |
| Lamotrigine ErLamotrigine | 20 | $4,885 |
| Oxcarbazepine | 43 | $4,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $78 | $60,77812 claims |
| UCB, Inc.Briviact, Neupro | $38 | $52,39839 claims |
| AbbVieUbrelvy, Qulipta | $146 | $43,85837 claims |
| Kyowa Kirin, Inc.Nourianz | $19 | $24,98713 claims |
| PfizerNurtec Odt | $32 | $23,55422 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $15 | $1,76716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 255 neurology providers in Alabama.
Other neurology in Cullman
- Christopher LagankeCullman$711K
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Emily RiserBirmingham$231K
- Nojan ValadiOpelika$219K
- Charles MarkleMobile$212K
- Timothy PrestleyTuscaloosa$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.